| Abstract |
Current therapy of ovarian cancer consists of primary surgical debulking
followed by chemotherapy. Drug selection in chemotherapy usually is not
based on individualized in vitro sensitivity studies but on reported
response rates of previous clinical trials. To understand the in vitro
cytotoxicity effect of drugs, a newly established ovarian cancer cell line
is used for this study. This cell line, OCPC-2-VGH, is isolated from an
ovarian papillary serous adenocarcinoma in 1991. The doubling time of
cells ranges from 44.85 to 58.98 hours in different conditional culture
medium with different percentage of fetal calf serum. Their chromosome
numbers ranged from 38 to 52 with a modal number of diploidy 46.
Immunohistochemical studies of OCPC-2-VGH cells for cytoskeleton, desmin,
fibronectin, myoglobin and vimentin are all positive, but epithelial
membrane antibody is not. The cytotoxic effects of six chemotherapeutic
drugs studied in vitro of OCPC-2-VGH cells are different. Some tumor cells
show almost complete cell kill at the low drug level; but others have only
a limited response at the high concentration. For OCPC-2 cells, the fifty
percent lethal dose of bleomycin is 15.1mug/ml; epirubcin 30.7mug/ml;
vincristine 123.4mug/ml; cis-platinum 310.9mug/ml; ifosphamide 564.6mug/ml;
and cyclophosphamide 4110.2mug/ml. The results demonstrate that the
proposed studies are capable of estimating an assay for the drug response
in individual ovarian cancer and thus may contribute to reducing of chemo-
resistance in clinical selection of ovarian cancer patients.
|
|---|
